# CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

> **NCT04062708** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 38 (actual)

## Conditions studied

- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **PROCEDURE:** Surgery
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT04062708
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-10
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04062708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04062708, "CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04062708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*